Tonix Pharmaceuticals Holding Corp. (TNXP) earnings
TNXP earnings moved a median of +2.22% by the close. Quarterly and annual TNXP reports and results, each read against the price at its own news timestamp. Back to the TNXP overview →
23 measured TNXP earnings events.
Where these TNXP earnings landedvs 19 measured TNXP earnings reactions
| Middle 50% of TNXP earnings reactions | -5.09% to +4.17% |
|---|---|
| Median reaction (to close) | +2.22% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 TNXP earnings events with a measured close landed between -5.09% and +4.17%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Tonix Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +5.16% | — | |
| Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights | Press release | — | — | |
| Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 | Press release | +1.50% | +3.80% | |
| Form 10-Q Tonix Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +5.72% | +5.56% | |
| Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights | Press release | +5.72% | +5.56% | |
| Form 10-K Tonix Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +1.34% | -3.15% | |
| Form 10-Q Tonix Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -0.67% | +2.22% | |
| Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights | Press release | -0.67% | +2.22% | |
| Form 10-Q Tonix Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -4.71% | — | |
| Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights | Press release | -4.71% | — | |
| Form 10-Q Tonix Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -2.79% | +4.29% | |
| Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | Press release | -2.79% | +4.29% | |
| Form 10-K Tonix Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +5.29% | -12.07% | |
| Form 10-Q Tonix Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +1.25% | -7.04% | |
| Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights | Press release | +2.70% | +2.69% | |
| Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights | Press release | +6.43% | -26.40% | |
| Form 10-Q Tonix Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +6.43% | -26.40% | |
| Form NT 10-Q Tonix Pharmaceuticals For: Jun 30 | SEC filing · Form NT | -4.00% | -7.68% | |
| Form 10-Q Tonix Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +4.17% | +4.17% | |
| Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights | Press release | +4.17% | +4.17% | |
| Form 10-K Tonix Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -2.63% | +0.32% | |
| Form 10-Q Tonix Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -4.30% | -0.21% | |
| Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights | Press release | -4.30% | -0.21% |
Keep exploring
More TNXP: analyst actions → · SEC filings → · TNXP overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Quest Diagnostics Incorporated (DGX) | 524 | +0.03% | 51% |
| STAAR Surgical Company (STAA) | 522 | -0.21% | 44% |
| Surface Oncology, Inc. (SURF) | 521 | -0.69% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.